Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer.

ABSTRACT: Prostate cancer (PCa) is the second leading cause of cancer-related death in the US. Androgen receptor (AR) signaling is the driver of both PCa development and progression and, thus, the major target of current in-use therapies. However, despite the survival benefit of second-generation inhibitors of AR signaling in the metastatic setting, resistance mechanisms inevitably occur. Thus, novel strategies are required to circumvent resistance occurrence and thereby to improve PCa survival. Among the key cellular processes that are regulated by androgens, metabolic reprogramming stands out because of its intricate links with cancer cell biology. In this review, we discuss how cancer metabolism and lipid metabolism in particular are regulated by androgens and contribute to the acquisition of res

SUBMITTER: Chetta P 

PROVIDER: S-EPMC9019185 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature